Previous studies have also show that c-Met inhibitor synergizes with TRAIL to induce papillary thyroid carcinoma (PTC) cell death, most likely through inhibition of abnormal c-Met activation and upregulation of DR5 [29]. The gene discussed is TNFRSF10B; the disease is differentiated thyroid carcinoma.